Literature DB >> 19591572

Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects.

Samir K Gupta1, Lauren Komarow, Roy M Gulick, Richard B Pollard, Gregory K Robbins, Nora Franceschini, Lynda A Szczech, Susan L Koletar, Robert C Kalayjian.   

Abstract

Because both renal disease and immune activation predict progression to acquired immunodeficiency syndrome (AIDS), we evaluated the associations between proteinuria>or=1+, as determined by dipstick analysis (7 [7%] of 1012 subjects); creatinine clearance of <90 mL/min (195 [18%] of 1071 subjects); and percentages of peripheral activated CD8 cells (CD8+CD38+HLA-DR+ cells) in antiretroviral-naive, human immunodeficiency virus (HIV)-infected subjects who were enrolled in AIDS Clinical Trials Group studies 384 and A5095. Proteinuria, but not creatinine clearance, was associated with higher percentages of CD8+CD38+HLA-DR+ cells (55% vs. 50%; P=.01), with even more pronounced differences noted among men and among blacks and Hispanics. Proteinuria may be a surrogate measurement of greater immune activation in HIV-infected patients initiating antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19591572      PMCID: PMC2858634          DOI: 10.1086/600890

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection.

Authors:  J A Winston; L A Bruggeman; M D Ross; J Jacobson; L Ross; V D D'Agati; P E Klotman; M E Klotman
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

2.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

3.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

Authors:  B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

4.  Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS.

Authors:  T Calvelli; T N Denny; H Paxton; R Gelman; J Kagan
Journal:  Cytometry       Date:  1993-10

5.  Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy.

Authors:  Lynda Anne Szczech; Donald R Hoover; Joseph G Feldman; Mardge H Cohen; Stephen J Gange; Lisa Goozé; Nancy R Rubin; Mary A Young; Xiaotao Cai; Qiuhu Shi; Wei Gao; Kathryn Anastos
Journal:  Clin Infect Dis       Date:  2004-09-27       Impact factor: 9.079

6.  Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women.

Authors:  Lytt I Gardner; Scott D Holmberg; John M Williamson; Lynda A Szczech; Charles C J Carpenter; Anne M Rompalo; Paula Schuman; Robert S Klein
Journal:  J Acquir Immune Defic Syndr       Date:  2003-02-01       Impact factor: 3.731

7.  Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

Authors:  Gregory K Robbins; Victor De Gruttola; Robert W Shafer; Laura M Smeaton; Sally W Snyder; Carla Pettinelli; Michael P Dubé; Margaret A Fischl; Richard B Pollard; Robert Delapenha; Linda Gedeon; Charles van der Horst; Robert L Murphy; Mark I Becker; Richard T D'Aquila; Stefano Vella; Thomas C Merigan; Martin S Hirsch
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

8.  A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population.

Authors:  Katherine Barraclough; Lee Er; Francisco Ng; Marianne Harris; Julio Montaner; Adeera Levin
Journal:  Nephron Clin Pract       Date:  2008-12-03

9.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

10.  T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

Authors:  Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Barry Bredt; Elilta Hagos; Harry Lampiris; Steven G Deeks
Journal:  J Infect Dis       Date:  2003-04-23       Impact factor: 5.226

View more
  14 in total

1.  Relationships between renal parameters and serum and urine markers of inflammation in those with and without HIV infection.

Authors:  Takashi Shinha; Deming Mi; Ziyue Liu; Christie M Orschell; Michael M Lederman; Samir K Gupta
Journal:  AIDS Res Hum Retroviruses       Date:  2015-02-26       Impact factor: 2.205

2.  Neither proteinuria nor albuminuria is associated with endothelial dysfunction in HIV-infected patients without diabetes or hypertension.

Authors:  Samir K Gupta; Changyu Shen; Kieren J Mather; Rajiv Agarwal; Michael P Dubé
Journal:  J Infect Dis       Date:  2011-10-19       Impact factor: 5.226

3.  Markers of renal disease and function are associated with systemic inflammation in HIV infection.

Authors:  S K Gupta; D Kitch; C Tierney; K Melbourne; B Ha; G A McComsey
Journal:  HIV Med       Date:  2015-05-20       Impact factor: 3.180

Review 4.  Renal issues in HIV infection.

Authors:  Robert C Kalayjian
Journal:  Curr HIV/AIDS Rep       Date:  2011-09       Impact factor: 5.071

5.  Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.

Authors:  Robert C Kalayjian; Bryan Lau; Rhoderick N Mechekano; Heidi M Crane; Benigno Rodriguez; Robert A Salata; Zipporah Krishnasami; James H Willig; Jeffrey N Martin; Richard D Moore; Joseph J Eron; Mari M Kitahata
Journal:  AIDS       Date:  2012-09-24       Impact factor: 4.177

6.  Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals.

Authors:  Robert C Kalayjian; Kunling Wu; Scott Evans; David B Clifford; Muraldihar Pallaki; Judith S Currier; Marlene Smryzynski
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

7.  A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy.

Authors:  Xue-Qing Yu; Ming Li; Hong Zhang; Hui-Qi Low; Xin Wei; Jin-Quan Wang; Liang-Dan Sun; Kar-Seng Sim; Yi Li; Jia-Nee Foo; Wei Wang; Zhi-Jian Li; Xian-Yong Yin; Xue-Qing Tang; Li Fan; Jian Chen; Rong-Shan Li; Jian-Xin Wan; Zhang-Suo Liu; Tan-Qi Lou; Li Zhu; Xiao-Jun Huang; Xue-Jun Zhang; Zhi-Hong Liu; Jian-Jun Liu
Journal:  Nat Genet       Date:  2011-12-25       Impact factor: 38.330

8.  High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial.

Authors:  Anuradha Ganesan; Nancy Crum-Cianflone; Jeanette Higgins; Jing Qin; Catherine Rehm; Julia Metcalf; Carolyn Brandt; Jean Vita; Catherine F Decker; Peter Sklar; Mary Bavaro; Sybil Tasker; Dean Follmann; Frank Maldarelli
Journal:  J Infect Dis       Date:  2011-02-15       Impact factor: 5.226

9.  Prevalence of proteinuria and elevated serum cystatin C among HIV-Infected Adolescents in the Reaching for Excellence in Adolescent Care and Health (REACH) study.

Authors:  Kristal J Aaron; Mirjam-Colette Kempf; Robert H Christenson; Craig M Wilson; Paul Muntner; Sadeep Shrestha
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-01       Impact factor: 3.731

10.  Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study.

Authors:  Samir K Gupta; Changyu Shen; Sharon M Moe; Lisa M Kamendulis; Mitchell Goldman; Michael P Dubé
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.